Cantor Fitzgerald Upgrades Dynex Capital (DX) to Buy; 3Q:11 Operating Metrics Generally Better than Peers
Get Alerts DX Hot Sheet
Price: $13.01 -0.31%
Rating Summary:
12 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 18
Rating Summary:
12 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 18
Join SI Premium – FREE
Cantor Fitzgerald upgraded Dynex Capital (NYSE: DX) from Hold to Buy with a price target of $9.15.
Cantor analyst, says, "With above-market risk-adjusted returns on its legacy CMBS portfolio, we expect Dynex to be able to sustain through 2012 an ROE similar to peers. Accordingly, we believe that Dynex should trade at least at book value. Our $9.15 target price (down from $9.50, due to a lower book value) assumes a book value multiple of 1.0x. Our 2012 dividend estimate of $1.08 equates to a 12.7% dividend yield. Share price appreciation plus dividends should produce a 12-month total return of 20%...Based on a 12-month total return above our 15% threshold, we are upgrading shares."
For more ratings news on Dynex Capital click here and for the rating history of Dynex Capital click here.
Shares of Dynex Capital closed at $8.53 yesterday.
Cantor analyst, says, "With above-market risk-adjusted returns on its legacy CMBS portfolio, we expect Dynex to be able to sustain through 2012 an ROE similar to peers. Accordingly, we believe that Dynex should trade at least at book value. Our $9.15 target price (down from $9.50, due to a lower book value) assumes a book value multiple of 1.0x. Our 2012 dividend estimate of $1.08 equates to a 12.7% dividend yield. Share price appreciation plus dividends should produce a 12-month total return of 20%...Based on a 12-month total return above our 15% threshold, we are upgrading shares."
For more ratings news on Dynex Capital click here and for the rating history of Dynex Capital click here.
Shares of Dynex Capital closed at $8.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Vivos Therapeutics reports 212% rise in Nevada patient referrals
- Wolfe Research Upgrades Moderna (MRNA) to Peerperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
Cantor Fitzgerald, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share